Department of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Japan.
Kawasaki Medical School General Medical Center, Japan.
J Diabetes Res. 2023 Sep 8;2023:8803172. doi: 10.1155/2023/8803172. eCollection 2023.
It has been shown that chronic hyperglycemia gradually decreases insulin biosynthesis and secretion which is accompanied by reduced expression of very important insulin gene transcription factors MafA and PDX-1. Such phenomena are well known as -cell glucose toxicity. It has been shown that the downregulation of MafA and/or PDX-1 expression considerably explains the molecular mechanism for glucose toxicity. However, it remained unknown which molecules can enhance MafA and/or PDX-1 expression levels. In this study, we comprehensively searched for G protein-coupled receptor (GPCR) compounds which can enhance MafA and/or PDX-1 expression levels using a small molecule compound library in pancreatic -cell line MIN6 cells and islets isolated from nondiabetic C57BL/6 J mice and obese type 2 diabetic C57BL/KsJ-db/db mice. We found that fulvestrant and dexmedetomidine hydrochloride increased MafA, PDX-1, or insulin expression levels in MIN6 cells. We confirmed that fulvestrant and dexmedetomidine hydrochloride increased MafA, PDX-1, or insulin expression levels in islets from nondiabetic mice as well. Furthermore, these reagents more clearly enhanced MafA, PDX-1, or insulin expression levels in islets from obese type 2 diabetic db/db mice in which MafA and PDX-1 expression levels are reduced due to glucose toxicity. In conclusion, fulvestrant and dexmedetomidine hydrochloride increased MafA, PDX-1, or insulin expression levels in MIN6 cells and islets from nondiabetic mice and obese type 2 diabetic db/db mice. To the best of our knowledge, this is the first report showing some molecule which can enhance MafA and/or PDX-1 expression levels. Therefore, although further extensive study is necessary, we think that the information in this study could be, at least in part, useful at some point such as in the development of new antidiabetes medicine based on the molecular mechanism of -cell glucose toxicity in the future.
已经表明,慢性高血糖逐渐降低胰岛素的生物合成和分泌,这伴随着非常重要的胰岛素基因转录因子 MafA 和 PDX-1 的表达减少。这种现象被称为β细胞葡萄糖毒性。已经表明,MafA 和/或 PDX-1 表达的下调相当程度上解释了葡萄糖毒性的分子机制。然而,尚不清楚哪些分子可以增强 MafA 和/或 PDX-1 的表达水平。在这项研究中,我们使用 MIN6 细胞系和来自非糖尿病 C57BL/6J 小鼠和肥胖 2 型糖尿病 C57BL/KsJ-db/db 小鼠的胰岛的小分子化合物文库,全面搜索可以增强 MafA 和/或 PDX-1 表达水平的 G 蛋白偶联受体 (GPCR) 化合物。我们发现氟维司群和右美托咪定盐酸盐可以增加 MIN6 细胞中的 MafA、PDX-1 或胰岛素的表达水平。我们证实氟维司群和右美托咪定盐酸盐也可以增加非糖尿病小鼠胰岛中的 MafA、PDX-1 或胰岛素的表达水平。此外,这些试剂在葡萄糖毒性导致 MafA 和 PDX-1 表达水平降低的肥胖 2 型糖尿病 db/db 小鼠的胰岛中更明显地增强了 MafA、PDX-1 或胰岛素的表达水平。总之,氟维司群和右美托咪定盐酸盐可以增加 MIN6 细胞和非糖尿病小鼠以及肥胖 2 型糖尿病 db/db 小鼠胰岛中的 MafA、PDX-1 或胰岛素的表达水平。据我们所知,这是首次报道可以增强 MafA 和/或 PDX-1 表达水平的某些分子。因此,尽管需要进一步广泛的研究,但我们认为本研究中的信息至少在某种程度上可能在未来基于β细胞葡萄糖毒性的分子机制开发新的抗糖尿病药物方面有用。